Time-series modeling of multiple sclerosis disease activity: A promising window on disease progression and repair potential?

SummaryThis article discusses and reviews advanced forms of serial morphometry in the context of a disease progression model in multiple sclerosis (MS). This model of disease activity distinguishes between overall disease activity and the proportion thereof that becomes permanent damage. This translates into a progression model that features a repair potential, which, when exhausted, marks the conversion or progression from relapsing to progressive disease. The level of repair capacity at a given time determines the rate of progression. Both clinical and MRI variables appear to be in support of such a model. We examine possible MRI markers for this repair capacity, particularly the short-term behavior of new MRI lesions, quantified by methods of time-series analysis—that is, capturing lesion dynamics in the form of MRI intensity change directly, rather than shape or volume change. Lower rates of individual lesion recovery may represent lower repair and greater proximity to a progressive stage. Individuals with low transient lesion turnover appear to undergo more rapid progression and atrophy. Because disease-modifying therapies aim to alter the pathophysiological chain of inflammation, demyelination, and axonal loss, a therapeutic effect may therefore be more readily apparent as a change in lesion dynamics and recovery rate and level, rather than a change in total lesion burden or enhancing lesion number.

[1]  F. Barkhof,et al.  Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients , 2005, Neurology.

[2]  J. Oger,et al.  Multiple sclerosis , 1988, Neurology.

[3]  Dominik S. Meier,et al.  Time-series analysis of MRI intensity patterns in multiple sclerosis , 2003, NeuroImage.

[4]  F. Barkhof,et al.  Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis , 1996, Annals of neurology.

[5]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. , 1989, Brain : a journal of neurology.

[6]  F. Barkhof,et al.  Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis , 1998, Annals of neurology.

[7]  Hans Lassmann,et al.  Recent neuropathological findings in MS—implications for diagnosis and therapy , 2004, Journal of Neurology.

[8]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[9]  Hans Lassmann,et al.  Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.

[10]  O. Andersen,et al.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. , 1993, Brain : a journal of neurology.

[11]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[12]  F. Jolesz,et al.  MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals , 2003, Neurology.

[13]  Richard H. Price,et al.  Black Holes , 1997 .

[14]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[15]  Iraj Derakhshan Improving hand function in chronic stroke: topography of the lesion and role of the corpus callosum. , 2003, Archives of neurology.

[16]  David H. Miller,et al.  A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. , 2002, The New England journal of medicine.

[17]  F. Barkhof,et al.  Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. , 2002, Archives of neurology.

[18]  G J Barker,et al.  The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. , 2000, Brain : a journal of neurology.

[19]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[20]  R. Rudick,et al.  Significance of T2 lesions in multiple sclerosis: A 13‐year longitudinal study , 2006, Annals of neurology.

[21]  R Kikinis,et al.  Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. , 2000, Archives of neurology.

[22]  H. Tremlett,et al.  Is late-onset multiple sclerosis associated with a worse outcome? , 2006, Neurology.

[23]  L. L. Cook,et al.  Resolution-Dependent Estimates of Multiple Sclerosis Lesion Loads , 2005, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[24]  B. Scheithauer,et al.  A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. , 1999, Brain : a journal of neurology.

[25]  David H. Miller,et al.  Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain , 2004, Annals of neurology.

[26]  M. Horsfield,et al.  Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. , 1995, Brain : a journal of neurology.

[27]  L. Kappos,et al.  Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS , 2006, Neurology.

[28]  Dominik S. Meier,et al.  MRI time series modeling of MS lesion development , 2006, NeuroImage.

[29]  M. Schwartz,et al.  Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases , 2005, Journal of the Neurological Sciences.

[30]  Hans Lassmann,et al.  Remyelination is extensive in a subset of multiple sclerosis patients. , 2006, Brain : a journal of neurology.

[31]  M. Rovaris,et al.  Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. , 2006, Brain : a journal of neurology.

[32]  E. Cho,et al.  Immunopathology of secondary‐progressive multiple sclerosis , 2001, Annals of neurology.

[33]  D. Paty,et al.  Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis , 1999 .

[34]  F. Barkhof,et al.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis , 1996, Neurology.

[35]  C. Lucchinetti,et al.  A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions , 2001, Annals of neurology.

[36]  R. Kikinis,et al.  Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage , 2000, Journal of Neuroimmunology.

[37]  N. Richert Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". , 2002, Neurology.

[38]  P M Matthews,et al.  Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging. , 1998, Brain : a journal of neurology.

[39]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[40]  A J Thompson,et al.  The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study , 2003, Journal of neurology, neurosurgery, and psychiatry.

[41]  P. Adeleine,et al.  Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. , 2003, Brain : a journal of neurology.

[42]  F. Barkhof,et al.  Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. , 1998, AJNR. American journal of neuroradiology.

[43]  M. Horsfield,et al.  A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. , 1998, Brain : a journal of neurology.

[44]  À. Rovira,et al.  Baseline MRI predicts future attacks and disability in clinically isolated syndromes , 2006, Neurology.

[45]  G. Barker,et al.  Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial , 1999 .

[46]  G. Barker,et al.  Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H , 1999, Neurology.

[47]  Ludwig Kappos,et al.  Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis , 1999, The Lancet.

[48]  A J Thompson,et al.  Is inflammation important in early PPMS? a longitudinal MRI study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[49]  M Rovaris,et al.  Whole brain volume changes in patients with progressive MS treated with cladribine , 2000, Neurology.

[50]  J A Frank,et al.  Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis , 1998, Annals of neurology.

[51]  D. Li,et al.  Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients , 1989, Annals of neurology.

[52]  Neal Jeffries,et al.  Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. , 2003, Brain : a journal of neurology.